CURIS INC (CRIS)
US2312693094 - Common Stock
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Curis to Present at Upcoming Healthcare Conferences in April
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Curis, Inc. (NASDAQ: CRIS) on behalf of the company's shareholders. The...
Curis files for $300M common stock offering (NASDAQ:CRIS)
Curis (CRIS) filed a prospectus for a mixed shelf offering to raise $25M. This is not an offer to sell the securities mentioned.
Curis Provides Fourth Quarter 2023 Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Provides Third Quarter 2023 Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Curis to Present at Upcoming Healthcare Conferences in September
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4...
Curis Provides Second Quarter 2023 Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...
Curis launches ~$15.1M registered direct offering (NASDAQ:CRIS)
Biotechnology company Curis (CRIS) said on Thursday that it is launching an ~$15.1M registered direct offering priced at-the-market.
Curis stock falls as FDA lifts partial clinical hold
Curis (CRIS) said Thursday the FDA removed the partial clinical hold on the company’s Phase 1/2 TakeAim Leukemia trial for lead candidate emavusertib. Read more here.
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...
Curis Announces $15.1 Million Registered Direct Offering
/PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK)...